Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Escitalopram plus Gui-Fu-Di-Huang pills for low-drive symptoms in depression with yang-deficiency constitution
ChiCTR2300073617Phase 4Not yet recruiting
- Sponsor
- Beijing Anding Hospital
- Start
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of escitalopram and gui fu di huang in major depressive disorder (MDD) (2 arms), sponsored by Beijing Anding Hospital. Primary endpoint: Fatigue Scale-14. Planned start Apr 2023; status: not yet recruiting.
02
Drugs
escitalopramgui fu di huang
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on ChiCTR2300073617.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300073617.